Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 6/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | CDK4 | P11802 | 4/20 | 0.33 |
| ▸ | CCND1 | P24385 | 4/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619434 | 0.85 | — | — | |
| SCHEMBL12251572 | 0.79 | — | — | |
| SCHEMBL21304668 | 0.79 | — | — | |
| SCHEMBL21233395 | 0.77 | — | — | |
| SCHEMBL21720314 | 0.73 | — | — | |
| SCHEMBL21784168 | 0.73 | — | — | |
| SCHEMBL21453406 | 0.71 | CCNE2 (0.34) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL803125 | 0.70 | CNR2 (0.31) | — | |
| SCHEMBL22545819 | 0.70 | — | — | |
| SCHEMBL20711402 | 0.68 | LMNA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-10358427-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-23 | — | — | US | disclosed |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CCNE2 2313/4885CCNE1 2961/4885CDK2 1013/4885 |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | CCNE2 823/4885CCNE1 1755/4885CDK2 296/4885 |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | CCNE2 2313/4885CCNE1 2961/4885CDK2 1013/4885 |
| US-10358427-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CCNE2 2313/4885CCNE1 2961/4885CDK2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.